natgillin/translations-raw huggingface dataset:
A method of treating or ameliorating a syndrome, disorder or disease, in a subject in need thereof comprising administering to the subject an effective amount of a compound of claim 14 or composition or medicament thereof in a combination therapy with one or more anti-inflammatory agents, or immunosuppressive agents, wherein said syndrome, disorder or disease is selected from the group consisting of: rheumatoid arthritis, and psoriasis. 
Spoj prema zahtjevu 1 za uporabu u postupku liječenja ili ublažavanja sindroma, bolesti ili poremećaja, kod subjekta kojem je potrebno koji sadrži davanje subjektu učinkovite količine spoja prema zahtjevu 1 ili njegovog pripravka ili lijeka u kombiniranoj terapiji s jednim ili više protuupalnih sredstava, ili imunosupresiva, pri čemu je navedeni sindrom, bolest ili poremećaj odabran iz skupine koju čine, reumatoidni artritis i psorijaza.
The nucleic acid molecule of claim 2, wherein the polynucleotide further comprises polynucleotides encoding at least one heterologous protein. 
Molekula nukleinske kiseline u skladu s patentnim zahtjevom 10, naznačena time što polinukleotid dodatno sadrži polinukleotid koji kodira najmanje jedan heterologni protein.
Threshold signal S4 from the noise threshold setting circuit 107 is applied to the comparator 109 (−) input, and the output S5 from the peak detector circuit 108 to the comparator 109 (+) input. 
- = kruga za usporedbu (109) koji uspoređuje izlazni signal kruga za podešavanje praga šuma (107) i kruga detekcije vršne vrijednosti (108), i
The anti-RGMa antibody of any one of claims 1-9, wherein the antibody further comprises an agent selected from the group consisting of: an immunoadhesion molecule, an imaging agent, and a therapeutic agent, wherein the imaging agent is selected from the group consisting of a radiolabel, an enzyme, a fluorescent label, a luminescent label, a bioluminescent label, a magnetic label, and biotin, and wherein the radiolabel is selected from the group consisting of 3H, 14C, 35S, 90Y, 99Tc, 111In, 125I, 131I, 177Lu, 166Ho, and 153Sm. 
Anti-RGMa protutijelo prema bilo kojem od zahtjeva 1-9, naznačeno time da protutijelo nadalje obuhvaća sredstvo odabrano iz skupine koju čine: imuno adhezivna molekula, sredstvo za snimanje, te terapijsko sredstvo, pri čemu je sredstvo za snimanje odabrano iz skupine koja sadrži radioobilježivač, enzim, fluorescentnu oznaku, svjetleću oznaku, bioluminiscentnu oznaku, magnetsku oznaku, i biotin, i pri čemu je radioobilježivač odabran iz skupine koju čine 3H, 14C, 358, 90Y, 99Tc, 111In, 1251, 1311, 177Lu, 166Ho, i 153Sm.
or an enantiomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, a solvate or a hydrate thereof. 
ili stereoizomer, tautomer, farmaceutski prihvatljiva sol, polimorf, solvat ili hidrat tog spoja.
The formulation of E28 or 29, wherein the anti-EGFR antibody, or antigen-binding portion thereof, comprises a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 13, and a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 18. 
Formulacija prema zahtjevu 15, naznačena time što anti-EGFR protutijelo sadrži varijabilnu regiju teškog lanca koja sadrži aminokiselinsku sekvencu navedene u SEQ ID NO: 13, 1 varijabilnu regiju lakog lanca koja sadrži aminokiselinsku sekvencu navedene u SEQ ID NO: 18.
is optionally substituted C6-C12 aryl, wherein said optional substituents are one to three R10 groups; 
je proizvoljno supstituiran C6-C12 aril, pri čemu su navedeni nezavisni supstituenti jedna do tri R10 skupine;
3,1 1b- cis -dihydrotetrabenazine for use in the prophylactic treatment of Huntington's disease in a patient identified as carrying the mutant gene responsible for Huntington's disease. 
Spoj, naznačen time, da služi za uporabu u profilaktičnom liječenju Huntington-ove bolesti kod pacijenta kod kojeg je utvrđeno da nosi mutantni gen odgovoran za Huntington-ovu bolest, pri čemu je spoj (+) izomer 3,1 1b-cis- dihidrotetrabenazina ili njegova farmaceutski prihvatljiva sol kako je određeno u zahtjevu 1.
Residue dissolved in CH2Cl2 and insoluble solids removed by filtration and discarded. 
Ostatak je otopljen u CH>CL 1 netopljive čvrste supstance su uklonjene filtracijom i odbačene.
The method according to the present invention allows to realize magnetic designs in magnetic and magnetic optically variable ink, which achieve an unprecedented graphical resolution. 
Postupkom sukladno predmetnom izumu omogućeno je dobivanje magnetskih uzoraka u magnetskoj i magnetskoj optički varijabilnoj tinti grafičke rezolucije kakva dosad nije postignuta.
The method according to claim 1, wherein a waterproof reinforcement element, such as a waterproof heat-sealing tape, which is preferably elastic and made of synthetic material, is applied directly to an inner surface of a lower edge of the membrane. The method according to claim 1, wherein said sole is overmolded directly onto the semimanufactured component of the upper. 
Postupak u skladu s jednim ili više od prethodnih patentnih zahtjeva, naznačen time, da se nepromočivi element za ojačavanje, poput nepromočive termoljepljive vrpce, koja je poželjno elastična 1 izrađena od sintetičkih materijala, postavlja izravno na unutarnju površinu donjeg ruba membrane (13).
The oil according to claim 1 comprising: a lipid fraction comprising fatty acids in concentrations of from 90% to 100% by weight C18:2 and C18:3 in concentrations of from 45% to 60% by weight; Omega 3 fatty acids in concentrations of from 0.5% to 2% by weight, and also comprising y-oryzanol in concentrations of from 0.01% to 0.10% over the total weight of the lipid fraction vitamin E in concentrations of from 0.01% to 0.40% over the weight of the lipid fraction. The oil according to claim 11 wherein said fatty acids are: 
Ulje prema jednom od zahtjeva 1 do 18, naznačeno time, da obuhvaća: lipidnu frakciju koja sadrži masne kiseline u koncentracijama od 90 do 100 masenih %, poželjno od 95 do 100 masenih %; vitamin F u koncentracijama od 45 do 60 masenih %, poželjno od 46 do 54 masenih %; omega 3 u koncentracijama od 0,5 do 2 masenih %, poželjno od 0,8 do 1,8 masenih %; i također obuhvaća y-orizanol u koncentracijama od 0,01 do 0,10 % preko ukupne mase lipidne frakcije, poželjno od 0,02 do 0,04 %; vitamin E u koncentracijama od 0,01 do 0,04 % preko mase lipidne frakcije, poželjno od 0,018 do 0,025 %.
In one embodiment, the replacement is designed to express histidines at positions 105, 106, 108, and 111. 
(a) na položaju odabranom iz 105, 106, 108, 111 1 njihove kombinacije;
A maleate salt of compound (I) represented by the following structural formula: wherein the molar ratio between compound (I) and maleic acid is 1:1. 
Maleat sol spoja (I) je predstavljena slijedećom strukturnom formulom: HR P20190564 T1 pri čemu je molarni odnos između spoja (1) i maleinske kiseline 1:1.
Use of a composition as defined in any one of claims 1 to 6 in the manufacture of a medicament for use in a method of treating or preventing a condition or disorder associated with a decrease or lack of release of a gut hormone secreted from L cells, the condition or disorder being selected from type I diabetes, type II diabetes, hypertriglyceridemia, obesity, metabolic syndrome, and polycystic ovary syndrome. 
Uporaba smjese definirane u bilo kojem od patentnih zahtjeva 1 do 6, naznačena time, što se koristi u izradi medikamenta za uporabu u metodi liječenja ili prevencije stanja ili poremećaja udruženih sa smanjenjem ili izostankom oslobađanja crijevnog hormona izlučenog iz I-stanica, stanje ili poremećaj biraju se između dijabetesa tipa i, dijabetesa tipa 11, hipertrigliceridemije, gojaznosti, metaboličkog sindroma i sindroma policističnih jajnika.
A conjugate according to claim 7 or a use according to claim 8, wherein said cancer is selected among lung, colon, esophagus, ovary, pancreas, skin, gastric, head and neck, bladder, sarcoma, prostate, hepatocellular, brain, adrenal, breast, endometrial, mesothelioma, renal, thyroid, hematological, carcinoid, melanoma, parathyroid, cervix, neuroblastoma, Wilms, testes, pituitary or pheochromocytoma cancers. 
Konjugat prema zahtjevu 7 ili uporaba prema zahtjevu 8, naznačeni time da je navedeni rak odabran od raka pluća, debelog crijeva, jednjaka, jajnika, gušterače, kože, želuca, glave 1 vrata, mokraćnog mjehura, sarkoma, raka prostate, hepatocelularnog raka, raka mozga, raka nadbubrežne žlijezde, dojke, endometrija, mezotelioma, raka bubrega, štitnjače, hematološkog raka, karcinoida, melanoma, paratiroidnog raka, vrata maternice, neuroblastoma, Wilmsovog tumora, raka testisa, raka hipofize ili feokromocitoma.
A compound according to claim 11, wherein R16 is C1-C6alkyl, C0--C3alkylheterocyclyl, C0-C3alkylcarbocyclyl, any of which is optionally substituted with hydroxy, halo, or C1-C6-C6alkoxy. 
Spoj u skladu sa zahtjevom 13, naznačen time, da R16 je C1-C6alkil, C0-C3alkilheterociklil, C0-C3alkilkarbociklil, od kojih bilo koji je po izboru supstituiran s hidroksi, halo ili C1-C6alkoksi.
A process for preparing Compound I-1•anhydrous form A: 
oblik kristalni spoj I-1 • anhidridni oblik A;
An antisense oligomer which causes skipping of the 53rd exon in the human dystrophin gene, consisting of a nucleotide sequence complementary to any one of the sequences consisting of the 32nd to the 56th or the 36th to the 56th nucleotides from the 5' end of the 53rd exon in the human dystrophin gene. 
Antisensni oligomer koji uzrokuje preskakanje 53. egzona u humanom distrofinskom genu, koji se sastoji od nukleotidne sekvence komplementarne nukleotidima 36. do 60. od 5' kraja 53. egzona humanog distrofinskog gena.
In a preferred embodiment, IL-18BP is fused to the constant region of an Ig molecule. 
U poželjnoj izvedbi, IL-18BP je fuzioniran za postojanu regiju Ig molekule.
Advantageously, the volume filling device has varying circumference to better be kept in place invaginated in the stomach wall of the patient. The stomach-to-stomach sutures or staples may be provided with fixation portions exhibiting a structure adapted to be in contact with the stomach wall to promote growth in of human tissue to secure long term placement of the volume filling device attached to the stomach wall. 
Uređaj u skladu s bilo kojim od patentnih zahtjeva 2 do 3, naznačen time što najmanje jedan od prvog 1 drugog međudjelujućeg elementa ima strukturu koja potiče rast tkiva (213), prilagođenu da bude u kontaktu s vanjskom stijenkom želuca radi osiguravanja dugotrajne pričvršćenosti uređaja za rastezanje na stijenku želuca.
The compound of claim 25 wherein R3 and R4 are, independently, H, halogen, methyl, methoxy, or trifluoromethyl. 
Spoj u skladu s patentnim zahtjevom 4 ili 6, naznačen time, da su R> i R* neovisno, H, halogen, metil, metoksi ili trifluorometil.
A pharmaceutical composition comprising the isolated antibody or fragment of claim 1 or 2 and a pharmaceutically acceptable carrier. 
Farmaceutski sastav koji sadrži izolirano antitijelo ili fragment prema bilo kojem od prethodnih patentnih zahtjeva i farmaceutski prihvatljiv nosač.
The information system according to claim 1, wherein the system comprises: a front member with holes for accommodating the optical element; a light source mounted on a circuit board and the system comprises a spacer for keeping the circuit board and the front member at a fixed distance. 
Informacijski sustav u skladu sa bilo kojim od prethodnih patentnih zahtjeva, gdje sustav sadrži: prednji član sa otvorima za smještaj optičkog elementa; izvor svjetlosti montiran na ploči strujnog kola i sustav sadrži razdjelnik (17) za držanje ploče strujnog kola i prednjeg člana na fiksnoj udaljenosti.
The method according to claim 1, wherein the add-on rate of resinous adhesive coating composition to the drying cylinder is less than 15 mg/m2 of drying cylinder surface. 
Metoda u skladu s patentnim zahtjevom 1, pri čemu je brzina dodavanja sastava smolastog adhezivnog omotača manja od 20 mg/m" površine cilindra za sušenje (86).
genetically modifying the germline of the rodent to comprise a human unrearranged immunoglobulin light chain variable region nucleic acid sequence comprising human VL and JL segments, and making the histidine substitution or insertion in the unrearranged human immunoglobulin light chain variable region nucleic acid sequence. 
(ID genetskog modificiranja zametne linije glodavca kako bi sadržavala humanu nepreuređenu sekvencu nukleinske kiseline varijabilne regije imunoglobulinskog lakog lanca koja sadrži humane segmente Vr 1 Jri provedbe supstitucije ili umetanja histidina u nepreuređenu humanu sekvencu nukleinske kiseline varijabilne Tegije imunoglobulinskog lakog lanca. 16.
A brewing chamber is an essentially enclosed chamber containing a beverage ingredient. 
Komora za kuhanje je u biti zatvorena komora koja sadrži sastojak od kojeg se pravi napitak.
Metabolites of the Compounds of the Invention 
Datum objave europskog patenta:
a pharmaceutical composition within the container, and 
(ii) farmaceutski pripravak unutar kontejnera, i
The composition according to claim 1 wherein the compound is (S)-1-cyclohexyl-2-((S)-5H-imidazo[5,1-a]isoindol-5-yl)ethanol or a pharmaceutically acceptable salt thereof. 
Pripravak sukladno zahtjevu 1, pri čemu je spoj (S)-1-cikloheks1l-2-((S)-5H-imidazo[5,1-alizoindol-5-iljetanol ili njegova farmaceutski prihvatljiva sol.
The method of claim 6 in which the amyloid disease is Alzheimer's disease. 
Spoj za uporabu iz patentnog zahtjeva 6, naznačen time, što je amiloidna bolest Alzheimerova bolest.
The invention preferably also relates to a solid formulation according to the invention, comprising a content of 1:10-1:40 of pimobendan in relation to citric acid anhydride. The preferred ratio is 1:20. 
Kruti pripravak prema bilo kojem od zahtjeva 1 do 11, naznačen time, da je sadržaj pimobendana u odnosu na sadržaj anhidrida limunske kiseline u omjeru 1:10 do 1:40, poželjno 1:20.
The present process will usually produce a considerable yield in the form of the present light stabilising composition. 
Sadašnjim postupkom će se obično dobiti znatan prinos u obliku sadašnjeg pripravka za stabiliziranje na svjetlo.
The anti-CTLA-4 antibody and 2'-deoxy-2',2'-difluorocytidine monohydrochloride (B-isomer), or pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to Claim 1, wherein the anti-CTLA-4 antibody is ipilimumab. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-B-D-glukopiranozid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema patentnom zahtjevu 1, gdje anti-CTLA-4 antitijelo je ipilimumab.
The process of item 13, wherein the temperature profile during the curing step shows a plateau-like form and wherein said temperature is preferably at least about 68 °C and the curing time is preferably in the range of from about 30 minutes to about 20 hours. 
Postupak prema zahtjevu 13, naznačen time da temperaturni profil tijekom koraka stvrdnjavanja pokazuje oblik platoa i gdje je navedena temperatura poželjno barem oko 68 "€ i gdje je vrijeme stvrdnjavanja poželjno u rasponu od oko 30 minuta do oko 20 sati.
A basic feature for this product, especially when it is intended to form structural portions in the car industry field, is in fact the tendency to be cold shaped, as well as a good mechanical resistance being fit to absorb shocks as a consequence of the crash tests recently developed in the car industry. 
Osnovna karakteristika za ovaj proizvod, posebno kada je namijenjen za formiranje strukturnih dijelova u području automobilske industrije, u stvari je njegova tendencija da bude hladno oblikovan, kao i dobra mehanička otpornost - tj. da je prilagođen da prigušuje udare kao posljedica testova sudara koji su nedavno razvijeni u automobilskoj industriji.
The wave-power unit according to claim 4, wherein the hollow body on its external surface is produced with radially extending flanges. The wave-power unit according to claim 4, wherein the hollow body on an external surface is provided with a radially extending disc-shaped element, which includes attachment means for attaching the guiding device to the housing of the generator. 
Jedinica pogonjena energijom valova u skladu s bilo kojim od patentnih zahtjeva 3-9, naznačena time što šuplje tijelo (12) na svojoj vanjskoj površini ima radijalno pružajući element u obliku diska (23), koji sadrži element za pričvršćivanje (24), namijenjen pričvršćivanju uređaja za navođenje na kućište (4) generatora.
an intake opening (11) arranged at the lower end of the casing (2), 
- = navedeno kućište (2) ima usisnu komoru (10) s navedenim ulaznim otvorom (11), -
Chromosome Aberration Analysis 
G. Analiza kromosomskih aberacija
The volume element is particularly efficiently stiffened by the granular material if the outer chamber has a volume fillable with the granular material, wherein the volume is completely, i.e. at 100%, filled with the granular material. 
Element za napuhavanje (10) u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što vanjska komora (14) ima volumen koji se može napuniti zrnatim materijalom, koji je posve napunjen zrnatim materijalom.
The compound or pharmaceutically acceptable salt thereof according to (1) above, wherein in formula (I), R5 is a phenyl group, a thienyl group, a naphthyl group, a dihydrobenzofuranyl group, a benzodioxolyl group, a benzothiadiazolyl group, a benzothienyl group or a quinolinyl group, each of which may be substituted with 1 to 3 substituents selected from the group F [wherein the group F consists of a C1-C6 alkyl group, a halogen atom, a trifluoromethyl group, a C1-C6 alkoxy group, a nitro group, a cyano group, and a C2-C7 alkanoyl group], or a C2-C8 alkenyl group which may be substituted with a phenyl group(s). 
Spoj ili njegova farmaceutski prihvatljiva sol prema zahtjevu 1, naznačen time da u formuli (1), R> je fenilna skupina, tienil skupina, naftil skupina, dihidrobenzofuranil skupina, benzodioksolil skupina, benzotiadiazolil skupina, benzotienil skupina ili kinolinil skupina, od kojih svaka može biti supstituirana sa 1 do 3 supstituenta odabrana iz skupine F [pri čemu skupina F sadrži C;-Cg alkilnu skupinu, atom halogena, trifluorometilnu skupinu, C,-CÂ« alkoksi skupinu, nitro skupinu, cijano skupinu, te C»-C; alkanoil skupinu], ili C>-Cg alkenil skupinu koja može biti supstituirana sa fenil skupinom(ama).
The formulation according to claim 10 which has a melting temperature of 36±3° C. or equal to 36±2° C. 
Formulacija u skladu s patentnim zahtjevima 10 ili 11, naznačena time, da ima temperaturu taljenja 36 ± 3 °C ili jednaku 36 ± 2 °C.
In some embodiments, the poly(lactic) acid-poly(ethylene)glycol copolymer has a number average molecular weight of about 15kDa to about 20kDa poly(lactic acid) and a number average molecular weight of about 4kDa to about 6kDa poly(ethylene)glycol. 
Terapeutska nanočestica prema zahtjevu 1, naznačena time da kopolimer poli(mliječna) kiselina-poli(etilen)glikol ima iznos prosječne molekularne težine od 15kDa do 20kDa poli(mliječna) kiselina i iznos prosječne molekularne težine od 4kDa do 6kDa poli(etilen)glikol.
The first primer of the pair of polynucleotide primers hybridizes specifically to the reverse complement sequence corresponding to that set forth in SEQ ID NO:3 from about nucleotide position 1 through about position 2050 and the second primer of said pair of polynucleotide primers hybridizes specifically to the sequence as set forth in SEQ ID NO:5 from about nucleotide position 2060 through about nucleotide position 12,208, and are extended toward each other to form an amplicon which comprises SEQ ID NO:1, said amplicon being diagnostic for the presence of MON89034 event DNA in the sample. 
(ii) se prva navedena DNA molekula specifično hibridizira sa SEQ ID NO: 5 na nukleotidnoj poziciji od oko 2060 do nukleotidne pozicije 12,208, 1 pri čemu spomenuta druga DNA molekula specifično hibridizira obrnuti redoslijed sekvence koja odgovara SEQ ID NO: 3 pozicije nukleotida od oko 1 do oko pozicije 2050. Par DNA molekula, koje sadrže: prvu DNA molekulu i drugu DNA molekulu, pri čemu se prva spomenuta DNA molekula sastoji od najmanje 18 u nizu poredanih nukleotida od bilo kojeg dijela transgene regije SEQ ID NO: 41li
The composition for the use according to r claim 1, wherein the cancer is selected from the group consisting of liver cancer, head and neck cancer, pancreatic cancer, gastric cancer, renal cancer, sarcoma, multiple myeloma, metastatic breast cancer, leukemia, lymphoma, esophageal cancer, brain tumor, glioma, bladder cancer, endometrial cancer, thyroid cancer, bile duct cancer, bone cancer, eye cancer (retinoblastoma), gallbladder cancer, pituitary cancer, colon cancer, colorectal cancer, salivary gland cancer, nasal pharyngeal cancer, breast cancer, lung cancer, prostate cancer, ovarian cancer, neuroblastoma, cervix cancer, melanoma, and skin cancer. The composition for the use according to claim 6, wherein the cancer is colorectal cancer. 
Spoj prema zahtjevu 12 gdje je u slučaju (1) spoj za liječenje poremećaja povezanog s neprirodnom aktivnošću signalnog puta Stat3 u subjekta i gdje se neprirodna aktivnost signalnog puta Stat3 može odrediti ekspresijom fosforiliranog Stat3 ili surogatom uzvodnog ili nizvodnog regulatora Stat3 fosforilacije i gdje je poremećaj (i) rak izabran iz skupine koju čine rak dojke, rak glave i vrata, rak pluća, rak jajnika, rak gušterače, kolorektalni karcinom, rak prostate, karcinom renalnih stanica, melanom, hepatocelularni karcinomi, rak cerviksa, sarkomi, tumori mozga, rakovi želuca, multipli mijelom, leukemija, limfomi;
(b6) an antigen-binding site comprising the H chain CDR 1, 2, and 3 having at least 70% sequence identity with amino acid sequences of SEQ ID NOs: 123, 124, and 125, respectively; 
(b6) mjesto vezanja antigena koje obuhvaća aminokiselinske sekvence H-lanca CDR-područja 1, 2 i 3 od SEQ ID NO: 123, 124 odnosno 125 (H-lanac CDR-područja od J326);
The humanized antibody molecule, or pharmaceutical composition, for use of claim 17, wherein the antibody molecule is administered by injection at a dose of 1 to 30 mg/kg, or, 1 to 5 mg/kg, optionally, wherein the antibody molecule is administered once a week to once every 2, 3, or 4 weeks or at a dose from 10 to 20 mg/kg every other week. 
Molekula humaniziranog antitijela, ili farmaceutska kompozicija, za uporabu prema patentnom zahtjevu 17, naznačena time što se molekula antitijela primjenjuje injekcijom u dozi od 1 do 30 mg/kg, ili, 1 do 5 mg/kg, opcionalno, gdje se molekula antitijela primjenjuje jednom tjedno do jednom na svaka 2, 3, ili 4 tjedna ili u dozi od 10 do 20 mg/kg svakog drugog tjedna.
Hydrophobicity of the insulin derivatives of the invention 
Broj objave europskog patenta:
obtaining a rodent embryonic stem cell comprising the humanized CD47 gene of (a); and 
(b) dobivanju glodavačke embrionske matične stanice koja sadrži humanizirani gen CD47 iz (a); i